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MaOBJECTIVES The objective of this clinical trial was to assess the safety and efﬁcacy of carotid BAT in advanced HF.
BACKGROUND Increased sympathetic and decreased parasympathetic activity contribute to heart failure (HF) symp-
toms and disease progression. Baroreﬂex activation therapy (BAT) results in centrally mediated reduction of sympathetic
outﬂow and increased parasympathetic activity.
METHODS Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions #35% on
chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and
Europe. They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT
(treatment group) for 6 months. The primary safety end point was system- and procedure-related major adverse
neurological and cardiovascular events. The primary efﬁcacy end points were changes in NYHA functional class,
quality-of-life score, and 6-minute hall walk distance.
RESULTS One hundred forty-six patients were randomized, 70 to control and 76 to treatment. The major adverse
neurological and cardiovascular event–free rate was 97.2% (lower 95% conﬁdence bound 91.4%). Patients assigned to
BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6  14 m vs.
1.5  13.2 m; p ¼ 0.004), quality-of-life score (–17.4  2.8 points vs. 2.1  3.1 points; p < 0.001), and NYHA functional
class ranking (p ¼ 0.002 for change in distribution). BAT signiﬁcantly reduced N-terminal pro–brain natriuretic peptide
(p ¼ 0.02) and was associated with a trend toward fewer days hospitalized for HF (p ¼ 0.08).
CONCLUSIONS BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro–brain natri-
uretic peptide, and possibly the burden of heart failure hospitalizations in patientswithGDMT-treatedNYHA functional class
III HF. (Barostim Neo System in the Treatment of Heart Failure; NCT01471860; Barostim HOPE4HF [Hope for Heart Failure]
Study; NCT01720160) (J Am Coll Cardiol HF 2015;3:487–96) © 2015 by the American College of Cardiology Foundation.D espite currently available drug and devicetherapies, 25% to 35% of patients with heartfailure (HF) and a reduced left ventricular
ejection fraction (LVEF) remain categorized in New
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in exercise capacity. They are also at substantial risk
for HF morbidity (e.g., HF hospitalization) and mor-
tality, thereby incurring signiﬁcant health care costs
(2). Thus, there is a need for new therapies that can
improve clinical status and outcomes in these
patients.
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AB BR E V I A T I O N S
AND ACRONYM S
BAT = baroreﬂex activation
therapy
BP = blood pressure
CRT = cardiac
resynchronization therapy
GDMT = guideline-directed
medical therapy
HF = heart failure
ICD = implantable
cardioverter-deﬁbrillator
LVEF = left ventricular
ejection fraction
MANCE = major adverse
neurological and cardiovascular
events
MLWHFQ = Minnesota Living
with Heart Failure
Questionnaire
NT-proBNP = N-terminal
pro–brain natriuretic peptide
NYHA = New York Heart
Association
OUS = outside the United
States
QoL = quality of life
US = United States
6MHW = 6-min hall walk
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withdrawal in the genesis of HF symptoms and in HF
disease progression (3,4). This autonomic imbalance
exerts adverse effects on the heart, blood vessels, and
kidneys, resulting in pathological left ventricular
remodeling, peripheral vasoconstriction, and salt and
water retention, respectively. These observations,
along with the success of adrenergic receptor blockade
in the treatment of HF, provide a rationale for thera-
pies that inhibit adrenergic activity, enhance para-
sympathetic activity, or, preferably, accomplish both
(5,6). Such therapies should ideally produce natural
physiological autonomic adaptation, as a trial of
total pharmacological adrenergic blockade with mox-
onidine worsened, rather than improved, clinical
outcomes (7).
One such therapy that has shown promise in
preliminary human studies of HF is baroreﬂex acti-
vation therapy (BAT), an electrical stimulation tech-
nology delivered by an implanted device resembling
a cardiac pacemaker (8,9). Stimulation of the carotid
baroreceptor with BAT results in centrally mediated
reduction of sympathetic outﬂow and increased
parasympathetic activity, resulting in increased arte-
rial and venous compliance and reduced peripheral
resistance. In patients with resistant hypertension,
BAT has been shown to be safe and effective for
lowering excessive blood pressure (BP) (9). In patients
with HF, a small, single-center, open-label study
demonstrated safety, a signiﬁcant and sustained 30%
reduction in sympathetic nerve activity measured
directly by peroneal nerve microneurography, and
improvement in HF clinical status assessed by changes
in NYHA functional class, QoL score, and 6-min hall
walk (6MHW) distance (10). Cardiac structure and
function, assessed by 3-dimensional echocardiogra-
phy, also improved. The rate of HF hospitalization was
also substantially decreased compared with the
12 months before implantation of the BAT system.
We report the results of a multinational, prospective,
randomized, parallel-controlled, clinical trial of
BAT in HF, performed to conﬁrm and extend these
ﬁndings.
METHODS
PATIENTS. Patients were eligible for the study if they
had moderately severe (NYHA functional class III)
chronic HF due to either ischemic or nonischemic
cardiomyopathy, with LVEFs of 35% or less. Patients
were required to be treated with chronic stable
guideline-directed medical therapy (GDMT) for HF
including a diuretic agent, an angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker, anda beta-blocker, if tolerated. Other inclusion
criteria were resting heart rate between 60
and 100 beats/min, systolic BP of at least 100
mm Hg, estimated glomerular ﬁltration rate
of at least 30 ml/min/1.73 m2, and a demon-
strated impairment in functional capacity as
evidenced by a 6MHW distance of 150 to
450 m. Patients were also required to be
suitable surgical candidates for BAT device
implantation, as determined by a study
cardiologist and surgeon, and had to meet
certain anatomical criteria, including bilat-
eral carotid bifurcations below the level of
the mandible and freedom from plaques or
atherosclerosis reducing the linear diameter
of the internal or distal common carotid ar-
teries by 50% or greater.
Patients were excluded from the study if
they had experienced NYHA functional class
IV HF symptoms with acute pulmonary
edema within 45 days of randomization or
myocardial infarction, unstable angina, syn-
cope, cerebrovascular accident, or aborted
sudden cardiac death (including appropriate
implantable cardioverter-deﬁbrillator [ICD]
therapies) during the 3 months before ran-
domization. Patients who had received
pacemakers or ICDs within 90 days of
enrollment were excluded. Patients who had received
cardiac resynchronization therapy (CRT) devices
within 6 months of enrollment or were anticipated
to receive them within 90 days were excluded to
minimize the likelihood that latent CRT effects could
inﬂuence study endpoints. Known or suspected bar-
oreﬂex failure or autonomic neuropathy necessitated
disqualiﬁcation, as did prior surgery, radiation, or
endovascular stent placement in the carotid sinus
region that limited the ability to place the carotid
sinus lead. Other exclusion criteria included current
treatment with inotropes, life expectancy <1 year,
body mass index >40 kg/m2, symptomatic un-
controlled bradyarrhythmias, previous or current
consideration of solid organ transplantation, asthma
requiring long-term medication, severe chronic
obstructive pulmonary disease or restrictive lung
disease, noncardiovascular conditions interfering
with 6MHW distance assessment, active malignancy,
nonadherence to medical therapy, and inability to
fulﬁll protocol requirements.
The protocol conformed to the Declaration of
Helsinki and was approved by the appropriate ethics
committees, institutional review boards, regional
ethics boards and regulatory authorities in Canada,
France, Germany, Italy, and the United States (US).
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protocol for each country was slightly different, but
major eligibility criteria and endpoints were harmo-
nized. Patients provided their written informed con-
sent before enrollment.
DEVICE DESCRIPTION, IMPLANTATION TECHNIQUE,
AND THERAPY TITRATION. The system for deliv-
ering BAT (Barostim neo system, CVRx, Inc., Minne-
apolis, Minnesota) consists of a carotid sinus lead and
a pulse generator. The lead comprises a 40-cm lead
body that terminates in a circular backer 7 mm
in diameter with a 2-mm iridium oxide–coated
platinum-iridium disk electrode centered on the
backer. System implantation is generally performed
by a vascular surgeon. The pulse generator is
implanted in the fashion of a pacemaker, by making a
subcutaneous infraclavicular chest wall pocket to
hold the pulse generator. Electrode implantation be-
gins by surgically exposing the carotid sinus through
a transverse cervical incision over the carotid bifur-
cation, with care taken to ensure that the adventitial
layers are preserved. The sinus region is then mapped
by temporarily placing the electrode in various
locations and applying electrical stimulation to
determine the location with greatest sensitivity to
BAT. Sensitivity is measured by observing hemody-
namic changes associated with acute baroreﬂex acti-
vation, namely, reductions in heart rate and/or BP
associated with increased parasympathetic trafﬁc
and/or decreased sympathetic trafﬁc, respectively.
With the correct position identiﬁed, the electrode is
directly afﬁxed by applying 6 sutures, evenly spaced
around the perimeter of the electrode backer, through
the backer and adventitia. The opposite end of the
lead is brought to the pulse generator pocket by
means of a subcutaneous tunnel and attached to the
pulse generator. All incisions are then closed and the
procedure is complete.
BAT dose is up-titrated over a series of follow-up
visits, much like medications are up-titrated. As
with medical therapy, the focus is on achieving a
therapeutic dose in the absence of side effects. Thus,
therapy is initiated at a moderate level in the absence
of side effects such as excessive reductions in heart
rate or BP. At later follow-up visits, therapy levels are
increased as the patient is able to tolerate higher
doses, with the objective of achieving full titration at
around 3 months. Because the electrode-baroreceptor
interface is unique to each patient, there is no stan-
dard dose of the therapy. The stated programmed
parameter statistics (see the Results section) repre-
sent the dosing in the average patient absent side
effects, thereby representing an analog to pharma-
cologic dosing.STUDY DESIGN. Patientsmeeting the criteria for entry
underwent the following baseline assessments: NYHA
functional class (11), QoL assessed by the Minnesota
Living with Heart Failure Questionnaire (MLWHFQ)
(12), 6MHW distance (assessed using a standardized
protocol [13]), cardiac structure and function as-
sessed by echocardiography, serum biomarkers
including N-terminal pro–brain natriuretic peptide
[NT-proBNP], and an accounting of HF medications.
After this initial evaluation, patients were ran-
domized (1:1) to receive ongoing GDMT alone (control
group) or ongoing GDMT plus BAT (treatment group).
Randomization occurred in permuted blocks to ensure
a balance between groups within centers. To receive a
randomization assignment, the intended date of BAT
initiation was identiﬁed as the “activation date.” The
activation date determined the schedule for all follow-
up visits for both the control and treatment groups.
Patients randomized to receive BAT were implanted
with the BAT system, as previously described. If a pre-
existing cardiac rhythm management device was pre-
sent, interaction testing was conducted to conﬁrm
unimpeded performance of the systems (14). BAT was
initiated either before discharge or within 2 weeks
after discharge. Mandatory follow-up visits for pa-
tients receiving BAT occurred at 2 weeks and at 1, 2, 3,
5, and 6months after initiation. The protocol called for
BAT to be gradually up-titrated over the ﬁrst several
visits. For control patients, the follow-up schedule in
the United States was identical to that for treatment
patients. Control patients outside the United States
(OUS) were seen at 3 and 6 months. Variables assessed
at baselinewere reevaluated in all patients at 6months
and constituted the evaluation of efﬁcacy. Adverse
event reporting was collected continuously. In the US,
hospitalization data were collected at baseline for the
6 months before enrollment and prospectively for
6 months after system activation, at all centers. OUS,
hospitalization data were collected retrospectively, at
a subset of centers.
STATISTICAL ANALYSIS. The primary safety objec-
tive was to determine the event-free rate of all
system- and procedure-related major adverse neuro-
logical and cardiovascular events (MANCE), and the
primary efﬁcacy end points were changes in NYHA
functional class, QoL score, and 6MHW distance.
MANCE included cardiovascular-related death,
stroke, cardiac arrest, acute myocardial infarction,
acute decompensated HF, hypertensive crisis, severe
complications of HF treatment, systemic and pulmo-
nary thromboembolism, infection requiring explan-
tation of any portion of the BAT system, cranial nerve
damage that was permanent (not resolved within
12 months of onset) or required invasive intervention
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491to correct, and events requiring nonelective major
restorative procedures. All potential MANCE under-
went an independent adjudication process. Multiple
MANCE adjudicated as causally or temporally linked
were treated as 1 event. Between-group differences in
changes of the following parameters constituted the
efﬁcacy evaluation: NYHA functional class, MLWHFQ
QoL score, 6MHW distance, cardiac structure and
function by echocardiography, and serum bio-
markers. Among these efﬁcacy end points, changes in
NYHA functional class, MLWHFQ QoL score, and
6MHW distance were considered to be of primary
interest. Other end points (echocardiographic pa-
rameters, biomarkers) were considered to be sup-
portive of these clinical measures. Echocardiographic
measurements were performed in a blinded fashion
by a central core laboratory. Within-group changes
and between-group differences in the rate of HF
hospitalization were considered to be exploratory
analyses. Cause of hospitalization was determined
using a blinded adjudication committee and process.
The sample size for this study was based on a
desire to obtain initial experience with this device in
the intended HF population. It was not determined
on the basis of statistical requirements for a formal
hypothesis test; rather it was chosen to inform
future research in terms of logistical considerations
and possible estimates of effect size and variability.
Effects on continuous variables that passed tests of
normality were assessed with paired Student t tests.
In the case of non-normal data, the Wilcoxon rank
sum test was used. Categorical variables were
analyzed using Fisher exact tests. Conﬁdence in-
tervals for proportions were calculated using the
exact binomial method. For HF hospitalization data,
comparisons between groups were based on the
exact permutation test or the negative binomial
method (when indicated). Hospitalization data were
annualized to account for variable periods of post-
randomization follow-up in those patients who did
not complete 6 months (e.g., because of death). For
the primary safety end point, no objective perfor-
mance criterion was pre-speciﬁed. For the primary
efﬁcacy variables, the statistical analysis plan did
not include adjustment for the multiplicity of com-
parisons, and a nominal p value of 0.05 or less was
considered suggestive of efﬁcacy. However, the
study steering committee agreed to apply a more
rigorous statistical approach whereby the study
could achieve its primary efﬁcacy end point if the
differences between groups in all 3 end points
(NYHA functional class, MLWHFQ QoL score, and
6MHW distance) had p values of 0.05 or less, if 2
end points had p values of 0.025 or less, or if 1 endpoint had a p value of 0.0167 or less, similar to the
methodology used in the MIRACLE (Multicenter
InSync Randomized Clinical Evaluation) trial (15).
Finally, several sensitivity analyses were performed
to determine the effect of patient dropouts (e.g.,
withdrawal of consent and loss to follow-up)
including last observation carried forward, best
case imputed for all patients, worst case imputed for
all patients, best case imputed for control and worst
case imputed for BAT, and mean imputed for all
patients. The best case/worst case analysis was also
done using the 10th- and 90th-percentile values
rather than minimal and maximal ones.
RESULTS
FOLLOW-UP AND DISPOSITION OF PATIENTS. Between
May 2012 and April 2014, 146 patients at 45 centers
were randomized in the trial; 70 (32 US and 38 OUS)
were assigned to the control group and 76 (40 US
and 36 OUS) were assigned to BAT. One patient in
the control group died before the activation date,
and 5 patients in the treatment group withdrew
consent or were withdrawn by the site before system
implantation and their activation dates. The 2
groups were similar with respect to baseline char-
acteristics, except for a signiﬁcantly worse QoL score
in the treatment group, a signiﬁcantly higher rate of
diuretic agent use in the treatment group, and a
trend toward a higher rate of HF hospitalization
before enrollment in the treatment group (Table 1).
The disposition of patients is shown in Figure 1. Of
the 69 patients assigned to the control group who
reached their activation dates, 15 did not complete 6
months of follow-up: 4 patients died, 5 withdrew
consent, 3 were lost to follow-up, and 3 missed the
visit. Of the 71 patients who received the BAT system
and reached their activation date, 7 did not complete
6 months of follow-up: 5 died and 2 withdrew
consent.
Poolability analysis indicated that the OUS and US
populations were generally similar, except for a
signiﬁcantly greater proportion of Caucasian patients
OUS compared with US (96% vs. 76%; p < 0.01), a
signiﬁcantly higher median NT-proBNP level OUS
compared with US (1,684 pg/ml [interquartile range:
652 to 4,446 pg/ml] vs. 742 pg/ml [interquartile range:
278 to 2,445 pg/ml]; p ¼ 0.03), and a signiﬁcantly
better mean QoL score OUS compared with US (43  19
vs. 51  23; p ¼ 0.05). Ivabradine, which is not avail-
able in the US, was used in 4 OUS patients.
SAFETY AND TOLERABILITY. The overall MANCE-
free rate was 97.2% (lower 95% conﬁdence bound
91.4%). Two system- or procedure-related MANCE
TABLE 1 Baseline Ch
Age, yrs
Female
Race (Caucasian)
Geography (U.S./Europ
Coronary artery disease
Atrial ﬁbrillation
Diabetes mellitus type
Hypertension
Chronic kidney disease
NYHA functional class
6-min walk, m
MLWHFQ QoL*
BMI, kg/m2
SBP, mm Hg
DBP, mm Hg
HR, beats/min
eGFR, ml/min
Creatinine, mg/dl
Cystatin C, mg/l
NT-proBNP, pg/ml
BNP*, pg/ml
LVEF, %
CRT
ICD
HF hospitalization rate
randomization
Number of medications
ACE inhibitors/ARBs
Beta-blockers
Calcium-channel block
Digitalis
Diuretic agents
Ivabradine
MRA
Values are mean  SD (n)
difference.
ACE ¼ angiotensin-con
BNP ¼ brain natriuretic pep
blood pressure; eGFR ¼ es
deﬁbrillator; MLWHFQ ¼ M
antagonist; NT-proBNP ¼
QoL ¼ quality of life; SBP
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492occurred during the course of the study, consisting of
2 hematomas adjudicated as related to the procedure.
The system- and procedure-related complication
event-free rate was 85.9% (lower 95% conﬁdence
bound 77.3%). All but 1 event occurred within 7 days
of implantation and resolved without residual side
effects. Complications included urinary retention,
urinary tract infection, hematoma (n ¼ 2), brady-
cardia, atrial arrhythmia (n ¼ 2), hypotension, wors-
ening HF, pneumothorax, and cervical neuralgia. The
majority of BAT patients (93%) had pre-existing car-
diac rhythm management devices. Rigorous testing at
the time of BAT system implantation revealed noaracteristics for Activated Subjects
Treatment Group Control Group
64  11 (71) 66  12 (69)
12.7 (9/71) 15.9 (11/69)
81.7 (58/71) 89.9 (62/69)
e/Canada) 53 (40)/45 (34)/3 (2) 46 (32)/51 (36)/3 (2)
66.2 (47/71) 68.1 (47/69)
45.1 (32/71) 43.5 (30/69)
2 36.6 (26/71) 33.3 (23/69)
57.6 (19/33) 56.8 (21/37)
33.8 (24/71) 24.6 (17/69)
III 98.6 (70/71) 100.0 (69/69)
297  79 (69) 308  85 (67)
51  21 (70) 43  22 (69)
29  5 (71) 29  5 (69)
115  18 (71) 119  17 (69)
72  11 (71) 73  11 (69)
73  11 (71) 75  12 (66)
58  21 (58) 59  19 (61)
1.4  0.5 (58) 1.3  0.4 (61)
1.3  0.6 (37) 1.3  0.4 (32)
1,422 (455–4,559) (49) 1,172 (548–2,558) (47)
123 (47–417) (17) 209 (34–517) (12)
24  7 (70) 25  7 (67)
33.8 (24/71) 30.4 (21/69)
88.7 (63/71) 85.5 (59/69)
before 0.63  1.47 (57) 0.36  1.12 (50)
4.8  1.6 (70) 4.4  1.9 (68)
78.9 (56/71) 79.4 (54/68)
87.3 (62/71) 85.3 (58/68)
ers 5.6 (4/71) 8.8 (6/68)
21.1 (15/71) 10.3 (7/68)
93.0 (66/71) 77.9 (53/68)
4.2 (3/71) 1.5 (1/68)
59.2 (42/71) 50.0 (34/68)
, % (n), median (interquartile range) (n), or % (n/N). *p # 0.05 for between-group
verting enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index;
tide; BP ¼ blood pressure; CRT ¼ cardiac resynchronization therapy; DBP ¼ diastolic
timated glomerular ﬁltration rate; HR ¼ heart rate; ICD ¼ implantable cardioverter-
innesota Living with Heart Failure Questionnaire; MRA ¼ mineralocorticoid receptor
N-terminal pro -brain natriuretic peptide; NYHA ¼ New York Heart Association;
¼ systolic blood pressure.device-device interactions impeding the performance
of either system.
Patients tolerated BAT well, as device program-
ming was titrated so that patients did not ex-
perience side effects (e.g., tingling or hypotension).
On average, pulse amplitude upon activation was
4.5  2.5 mA and steadily increased to 6.8  2.4 mA at
3 months, remaining stable thereafter. Pulse width
and frequency were stable throughout follow-up,
averaging 108.8  75.8 ms and 61.9  20.8 pulses/s,
respectively. Symptoms associated with therapy
titration were rare, with a 0.67% incidence of tran-
sient bradycardia or hypotension requiring inter-
vention beyond acute device reprogramming. No
changes were detected in diastolic BP in either group.
Systolic BP trended downward in control patients,
while it trended upward in the treatment group.
This difference in effect of BAT on systolic BP
reached statistical signiﬁcance (8.5  3.8 mm Hg;
p ¼ 0.03), while pulse pressure also demonstrated a
signiﬁcant increase (9.6  3.2 mm Hg; p ¼ 0.004)
(Figure 2).
EFFICACY. At 6 months, statistically signiﬁcant im-
provements were observed in NYHA functional class,
MLWHFQ QoL score, and 6MHW distance in BAT
patients compared with control patients (p ¼ 0.002,
p < 0.001, and p ¼ 0.004, respectively) (Table 2). More
patients in the treatment group (55%) demonstrated
at least a 1-class improvement in NYHA functional
class, compared with the control group (24%). The
between-group difference in MLWHFQ QoL score
was 19.5  4.2 points, favoring BAT. Likewise, the
between-group difference in 6MHW distance was
58.1  19.8 m, also favoring BAT. Multiple sensitivity
analyses generally supported the signiﬁcance of these
ﬁndings, with the exception of the best case/worst case
sensitivity analyses.
NT-proBNP was reduced in the treatment group and
increased in the control group, with a signiﬁcant
between-group difference (median 69.0 pg/ml
[interquartile range: 504 to 198 pg/ml] vs. 129.5
pg/ml [interquartile range: 67 to 619 pg/ml]; p ¼
0.02). No signiﬁcant changes were observed in other
biomarkers (creatinine, estimated glomerular ﬁltra-
tion rate, and cystatin C). Echocardiographic analysis
indicated a nonsigniﬁcant trend toward improved
LVEF in the BAT group and a slight reduction in the
control group, with a between-group difference of
2.5  1.7% (p ¼ 0.15). Other echocardiographic param-
eters were not signiﬁcantly altered by BAT.
The effect of BAT on the rate of HF hospitalization
and on the mean number of days hospitalized for
HF is summarized in Table 3. During the 6 months
before enrollment, there was an apparent difference
FIGURE 1 Disposition of All Randomized Subjects Through 6 Months
See text for details.
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493between groups in the annualized rate of HF hospi-
talization and the mean number of days hospitalized
for HF, especially in the US (p ¼ 0.08 and p ¼ 0.05,
respectively). Globally, there was a signiﬁcant
reduction in the rate of HF hospitalization from pre-
to post-enrollment in the treatment group (0.63  1.5
to 0.14  0.5 hospitalizations/patient/year; p ¼ 0.01),
with no change seen in the control group (0.36  1.1 to
0.31  0.97 hospitalizations/patient/year; p ¼ 0.85).
However, the between-group difference in the post-
randomization rate of HF hospitalization did not
reach statistical signiﬁcance (p ¼ 0.35). The effect of
BAT on the mean number of days hospitalized for HF
followed a similar pattern of signiﬁcance and non-
signiﬁcance. However, the between-group differenceFIGURE 2 Effect of BAT on BP
Baroreﬂex activation therapy (BAT) signiﬁcantly increased systolic blood
BP. In contrast, there were trends toward decreasing systolic BP and pu
Med Mgmt ¼ medical management; PP ¼ pulse pressure; SBP ¼ systoliin post-randomization days hospitalized for HF
demonstrated a trend favoring the treatment group
(p ¼ 0.08).
DISCUSSION
The results of the present study indicate that BAT is
safe and signiﬁcantly improves NYHA functional
class, QoL, and exercise capacity in patients with
NYHA functional class III HF with reduced LVEFs.
The magnitude of these beneﬁts was similar to, if not
greater than, that reported with currently available
effective drug and device therapies for HF, and yet
they were seen in patients already receiving
these therapies (15,16). These results corroborate thepressure (BP) (A) and pulse pressure (B), with no effect on diastolic
lse pressure in the control group. DBP ¼ diastolic blood pressure;
c blood pressure.
TABLE 2 Effect of BAT on Primary Efﬁcacy End Points (Change From Baseline to
6 Months)
Treatment Group Control Group Difference
n Mean  SE n Mean  SE Mean  SE p Value
NYHA functional class
(% improved,
same, worse)
64 55%, 42%, 3% 54 24%, 67%, 9% 0.002
MLWHFQ QoL 64 17.4*  2.8 54 2.1  3.1 19.5  4.2 <0.001
6MHW distance (m) 56 59.6*  14.1 43 1.5  13.2 58.1  19.8 0.004
*p < 0.001 for within-group change.
6MHW ¼ 6-minute hall walk; SE ¼ standard error; other abbreviations as in Table 1.
TABLE 3 Effect of B
Number of HF hospital
Before enrollment
Post-randomization
Change from pre to
Negative binomial 6
post-randomizati
HF hospitalizations day
Before enrollment
Post-randomization
Change from pre to
Negative binomial 6
post-randomizati
Values are mean  SD unle
within-group comparisons
model.
BAT ¼ baroreﬂex activat
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494single-center, open-label experience previously re-
ported by Gronda et al. (10). The present study ex-
tends the results of Gronda et al. by demonstrating
signiﬁcant improvement in NT-proBNP, a signiﬁcant
correlate of clinical outcome in patients with HF (17).
Although the present study was not adequately
powered to evaluate clinical outcomes, the effect of
BAT on the rate of HF hospitalization and on the mean
number of days hospitalized for HF was explored to
aid in the design of future studies. An apparent
imbalance between groups in both measures at base-
line (i.e., during the 6 months before enrollment)
makes the interpretation of post-randomization HF
hospitalization data difﬁcult. However, there was a
signiﬁcant reduction in both the rate of HF hospitali-
zation and the mean number of days hospitalized for
HF from pre- to post-enrollment in patients treated
with BAT, which was not seen in patients randomized
to the control group, and the post-randomization
between-group difference in the average number ofAT on the Annualized Rate of HF Hospitalization and the Mean Number o
US and OUS
Device
(n ¼ 57)
Med Mgmt
(n ¼ 50)
Difference
(Mean  SE)
Device
(n ¼ 38)
Me
(
izations per year
0.63  1.5 0.36  1.1 0.27  0.3 0.58  1.2 0.
0.14  0.5 0.31  1.0 0.17  0.1 0.11  0.5 0.2
post 0.49†  0.2 0.05  0.2 0.44  0.3 0.47†  0.2 0.
months
on
0.12 0.25 52% RR‡ 0.07
s per year
6.95  20.7 2.40  8.6 4.55  3.1 2.21  4.6 0.4
0.67  2.5 2.48  7.4 1.82*  1.0 0.58  2.5 0.8
post 6.28†  2.7 0.08  1.7 6.36†  3.3 1.63*  0.8 0.4
months
on
0.38 2.10 82% RR*‡ 0.09
ss otherwise noted. The p values for between-group comparisons are based on the exact p
are based on a paired Wilcoxon test. *p # 0.10. †p # 0.05. ‡RR ¼ relative reduction adjusted
ion therapy; HF ¼ heart failure; OUS ¼ outside United States; SE ¼ standard error; US ¼ Udays hospitalized for HF nearly reached statistical
signiﬁcance.
The safety proﬁle of BAT in HF is comparable with
that observed in the resistant hypertensive popula-
tion and similar to that of a pacemaker (9). The BAT
system was safely implanted with few complications,
resulting in no untoward effects, and the therapy was
very well tolerated. The risk for major adverse
neurological and cardiovascular events over 6 months
(the primary safety end point) compares favorably
with similar device-based therapies. No interactions
with implantable cardiac rhythm management de-
vices (pacemakers or ICDs) were seen. This observa-
tion is important, because a majority of patients with
HF with reduced ejection fractions are indicated for
such devices (1).
Also of consequence, BAT did not produce hy-
potension in these normotensive patients with HF,
in contrast to the known BP-lowering effect of BAT
in hypertensive subjects. Rather, BAT resulted in
signiﬁcant increases in systolic BP and pulse pres-
sure in these patients with HF, perhaps caused by
improved stroke volume due to reduced vascular
resistance. This effect of BAT to maintain or
improve BP in patients with HF is not only impor-
tant from the safety standpoint but may also
contribute to efﬁcacy, because lower BPs are asso-
ciated with poorer outcomes in HF patients (18).
Mechanistically, the postulated decrease in vascular
resistance may be due to previously demonstrated
reductions in peripheral sympathetic nerve activity
with BAT (10).
STUDY LIMITATIONS. The relatively small number of
patients studied may limit the interpretation of somef Days Hospitalized for HF
US OUS
d Mgmt
n ¼ 32)
Difference
(Mean  SE)
Device
(n ¼ 19)
Med Mgmt
(n ¼ 18)
Difference
(Mean  SE)
13  0.5 0.45*  0.2 0.74  1.9 0.78  1.7 0.04  0.6
4  1.0 0.13  0.2 0.21  0.6 0.44  0.9 0.23  0.2
11  0.2 0.58†  0.3 0.53  0.5 0.33  0.5 0.19  0.7
0.16 54% RR‡ 0.20 0.42 52% RR‡
4  1.7 1.77†  0.9 16.42  33.9 5.89  13.6 10.53  8.6
8  4.0 0.30  0.8 0.84  2.6 5.33  10.8 4.49*  2.5
4  0.8 2.07*  1.2 15.58  7.7 0.56  4.5 15.02  9.1
0.67 86% RR‡ 0.80 4.91 84% RR‡
ermutation test (except for the negative binomial comparison). The p values for the
for 12 months before enrollment HF hospitalizations based on the negative binomial
nited States.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Despite
currently available drug and device therapies, many patients with
HF remain highly symptomatic and limited in their daily activities.
Carotid BAT results in centrally mediated reduction of sympa-
thetic outﬂow and increased parasympathetic activity, thus
potentially restoring autonomic balance in patients with HF.
TRANSLATIONAL OUTLOOK: The present study indicates
that BAT is safe and signiﬁcantly improves NYHA functional
class, QoL, exercise capacity, NT-proBNP, and possibly the
burden of HF hospitalizations in patients with NYHA functional
class III HF with reduced LVEFs. If these observations are
conﬁrmed in larger studies, BAT may offer a new addition for the
treatment of patients with advanced HF with reduced LVEFs.
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495of the results of the present study. Another potential
limitation may be the lack of patient blinding and a
sham control, leading to a “placebo effect” in the
treatment arm, or a lack of blinding in investigator
assessment of end points, leading to bias. However,
the magnitude of improvement in the primary end
points is substantially larger than that attributable to
such a placebo effect or bias in prior device trials. For
example, in prior studies of CRT, the implantation of
an inactive device was associated with a 10-m
improvement in 6MHW distance (15), a placebo ef-
fect that falls far short of the nearly 60-m improve-
ment seen with BAT in the present study. In addition,
at least 1 of the end points signiﬁcantly improved by
BAT, NT-proBNP, is not prone to a placebo effect. The
difference in follow-up schedule between study
groups OUS has the potential to bias the results.
However, there were no statistically signiﬁcant dif-
ferences in the treatment effect between the US and
OUS subjects. Similarly, the differential collection of
hospitalization data by world region could also
introduce bias. However, data presented in Table 3
indicate similar hospitalization trends in both major
geographies of the study.
Our study results are strengthened by a high
standard of baseline pharmacologic and device-based
therapy (87% ICD, 32% CRT). For comparison, in a
recently published HF drug trial, only 15% of patients
received ICDs and 7% received CRT devices, despite a
quite similar ejection fraction boundary for inclusion
(19). Hence, our results indicate that HF therapy can
be improved in an already very well treated, but very
symptomatic HF population.
CONCLUSIONS
In summary, BAT is safe and signiﬁcantly im-
proves functional status, QoL, exercise capacity,
and NT-proBNP in well-treated patients with NYHA
functional class III HF. The data also support thepossibly that BAT reduces the rate of HF hospitaliza-
tion and the number of days hospitalized for HF.
This latter observation should be conﬁrmed in an
adequately powered prospective outcome trial.
ACKNOWLEDGMENTS The authors would like to
acknowledge the following individuals for their con-
tributions: Members of the Adverse Events Committee:
George S. Goding, Jr., MD, Jeffrey A. Kohen, MD, J.
Gregory Modrall, MD, Marc J. Semigran, MD, and
Brett A. Simon, MD, PhD. Members of the Data
Monitoring Committee: Martin C. Burke, DO, William
H. Gaasch, MD, Theo Meyer, MD, DPhil, and Thomas
Naslund, MD. Director of the Echocardiography Core
Laboratory: Julio Chirinos, MD, PhD.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
William T. Abraham, Division of Cardiovascular
Medicine, Davis Heart and Lung Research Institute,
473 West 12th Avenue, Room 110P, Columbus, Ohio
43210-1252. E-mail: william.abraham@osumc.edu.RE F E RENCE S1. Yancy CW, Jessup M, Bozkurt B, et al. 2013
ACCF/AHA guideline for the management of heart
failure. Circulation 2013;128:e240–327.
2. Go AS, Mozaffarian D, Roger VL, et al. Heart
disease and stroke statistics—2014 update: a
report from the American Heart Association. Cir-
culation 2014;129:e28–292.
3. Floras JS. Sympathetic nervous system activa-
tion in human heart failure: clinical implications of
an updated model. J Am Coll Cardiol 2009;54:
375–85.
4. Ponikowski P, Anker SD, Chua TP, et al.
Depressed heart rate variability as anindependent predictor of death in chronic
congestive heart failure secondary to ischemic or
idiopathic dilated cardiomyopathy. Am J Cardiol
1997;79:1645–50.
5. MERIT-HF Study Group. Effect of metoprolol
CR/XL in chronic heart failure: Metoprolol CR/XL
Randomised Intervention Trial in-Congestive
Heart Failure (MERIT-HF). Lancet 1999;353:
2001–7.
6. Bristow MR, Gilbert EM, Abraham WT, et al.
Carvedilol produces dose-related improvements in
left ventricular function and survival in subjects
with chronic heart failure. Circulation 1996;94:
2817–25.7. Cohn JN, Pfeffer MA, Rouleau J, et al. Adverse
mortality effect of central sympathetic inhibition
with sustained-release moxonidine in patients
with heart failure (MOXCON). Eur J Heart Fail
2003;5:659–67.
8. Georgakopoulos D, Little WC, Abraham WT,
Weaver FA, Zile MR. Chronic baroreﬂex activation:
a potential therapeutic approach to heart failure
with preserved ejection fraction. J Card Fail 2011;
17:167–78.
9. Hoppe UC, Brandt MC, Wachter R, et al. Mini-
mally invasive system for baroreﬂex activation
therapy chronically lowers blood pressure with
pacemaker-like safety proﬁle: results from the
Abraham et al. J A C C : H E A R T F A I L U R E V O L . 3 , N O . 6 , 2 0 1 5
Baroreﬂex Activation Therapy for HF J U N E 2 0 1 5 : 4 8 7 – 9 6
496Barostim neo trial. J Am Soc Hypertens 2012;6:
270–6.
10. Gronda E, Seravalle G, Brambilla G, et al.
Chronic baroreﬂex activation effects on sympa-
thetic nerve trafﬁc, baroreﬂex function, and cardiac
haemodynamics inheart failure: aproof-of-concept
study. Eur J Heart Fail 2014;16:977–83.
11. The Criteria Committee of the New York Heart
Association. Nomenclature and Criteria for Diag-
nosis of Diseases of the Heart and Great Vessels.
9th ed. Boston: Little, Brown; 1994.
12. Rector RS, Kubo SH, Cohn JN. Patients’ self-
assessment of their congestive heart failure. II.
Content, reliability, and validity of a new mea-
sure—the Minnesota Living with Heart Failure
Questionnaire. Heart Fail 1987;3:198–209.
13. Guyatt GH, Sullivan MJ, Thompson PJ, et al.
The 6-minute walk: a new measure of exercise
capacity in patients with chronic heart failure. Can
Med Assoc J 1985;132:919–23.14. Madershahian N, Scherner M,Müller-Ehmsen J,
et al. Baroreﬂex activation therapy in patients with
pre-existing implantable cardioverter-deﬁbrillator:
compatible, complementary therapies. Europace
2014;16:861–5.
15. Abraham WT, Fisher WG, Smith AL, et al.
Cardiac resynchronization in chronic heart failure.
N Engl J Med 2002;346:1845–53.
16. Fowler MB. Beta-blockers in heart failure. Do
they improve the quality as well as the quantity of
life? Eur Heart J 1998;19 Suppl P:P17–25.
17. Pﬁster R, Diedrichs H, Schiedermair A, et al.
Prognostic impact of NT-proBNP and renal func-
tion in comparison to contemporary multi-marker
risk scores in heart failure patients. Eur J Heart
Fail 2008;10:315–20.
18. O’Connor CM, Abraham WT, Albert NM, et al.
Predictors of mortality after discharge in patients
hospitalized with heart failure: an analysis from the
Organized Program to Initiate Lifesaving Treatmentin Hospitalized Patients with Heart Failure (OPTI-
MIZE-HF). Am Heart J 2008;156:662–73.
19. McMurray JJ, Packer M, Desai AS, et al.
Angiotensin-neprilysin inhibition versus enalapril
in heart failure. N Engl J Med 2014;371:
993–1004.KEY WORDS autonomic nervous system,
baroreﬂex, device, heart failure, randomized
controlled trial
APPENDIX For a list of the participants in the
study, please see the online version of this
article.
Go to http://cme.jaccjournals.org
to take the CME quiz for this
article.
